Navigation Links
Rutgers laboratory helped to create new HIV drug
Date:6/23/2011

Two decades after a Rutgers team began working with legendary drug developer Paul Janssen, founder of a Belgian subsidiary of pharmaceutical giant Johnson & Johnson in an effort to create new and potent drugs to fight AIDS, the U.S. Food and Drug Administration has approved the second anti-HIV drug that came from this collaboration.

"For a drug to successfully make it to the finish line, countless obstacles must be overcome," said Eddy Arnold, Board of Governors Professor of Chemistry and Chemical Biology, and a resident faculty member of the Center for Advanced Biotechnology and Medicine who led the Rutgers team. "As a researcher in biomedical sciences I can tell you that helping to create new medicines is something you always dream about."

The newest AIDS drug, (rilpivirine) Edurant the first to be approved by the FDA in the last three years and manufactured by Tibotec Therapeutics, a subsidiary of J&J was developed in 2001 and took a decade to make its way through the regulatory process and clinical trials.

"From the beginning, we knew this would be a long-term project," said Arnold whose research group team received $20 million mostly from the National Institutes of Health as well as two prestigious MERIT (Method to Extend Research in Time) NIH awards, an honor bestowed on less than 5 percent of NIH grant recipients. "Many challenges have been faced and overall it has been more like a marathon than anything else."

Resistant strains of HIV are a growing medical problem because the virus is constantly mutating, and the changes can cause existing AIDS drugs from being able to work. Arnold's team developed innovative models that explain not only why Edurant, approved by the FDA last month, and Intelence, approved in 2008, are particularly effective against drug-resistant viruses but can also be used in the development of treatments for a wide variety of other diseases. The gist of the model is that flexibility of a drug can allow it to adapt to changes in HIV.

Clinical trials for Edurant, which included more than 1,300 adults with HIV, indicated that 83 percent of those who were given this anti-AIDS drug for a 48-week period had undetected levels of HIV in their blood at the conclusion of the clinical trial. The new drug can be prescribed as a once-a-day pill to HIV-positive adults who have not received any prior treatment or therapy. Besides being available in the United States, a generic form of the drug will be made available to millions of people in Saharan Africa, India and other developing nations.

"Development of this newest AIDS drug represents a wonderful example of the biomedical power that can be harnessed by scientific collaborations and partnerships between university, government, and private sector research enterprises," said Kenneth J. Breslauer, dean of Life and Health Sciences. "No more satisfying and important outcome can result from university research."

This scientific collaboration began in 1987 when the Rutgers team entered into a partnership with Stephen Hughes, an AIDS researcher at the National Cancer Institute. Both were interested in understanding the molecular structure and function of reverse transcriptase, an essential part of the AIDS virus, not only for its fundamental significance, but also because they believed it would provide guidance for the design of more effective drugs.

Three years later, Arnold reached out to Janssen at the J&J subsidiary, Janssen Pharmaceutica, which had developed promising compounds to prevent reverse transcriptase from being able to create a genetic copy of the AIDS virus. The Rutgers team suggested that crystal structures of the compound created by Janssen, bound to the reverse transcriptase enzyme, could help the company understand and improve its chemical structures and be used to develop more effective AIDS drugs.

They worked together for the next 13 years, during which time Janssen provided $2 million to help fund the Rutgers team's research efforts to develop drugs that would be effective against drug-resistant mutants of the AIDS virus. A pivotal breakthrough happened in 1998 when dapavirine -- which works by preventing HIV from replicating its genetic material after the virus enters a healthy cell was developed. Further refinements of the drug led to creation of two anti-AIDS drugs: Intelence approved by the FDA in 2008, and Edurant, which came on the market in May and has shown exceptional potency against drug resistant HIV.


'/>"/>

Contact: Robin Lally
rlally@ur.rutgers.edu
732-932-7084 x652
Rutgers University
Source:Eurekalert

Related biology news :

1. Rutgers scholar authors definitive biography of reproductive medicine pioneer
2. Rutgers receives US$10 million to establish Institute for Food, Nutrition and Health
3. Evolution and climate change research advances at Rutgers-Camden
4. Rutgers study finds many consumers ignore food product recalls
5. Rutgers research tackles childhood epilepsy
6. Rutgers-Camden developing enzyme function database
7. Rutgers to collaborate in $3.4 million effort to improve prostate cancer identification using MRI
8. TAXIS Pharmaceuticals licenses novel antimicrobial technology from Rutgers and UMDNJ
9. NSF grant supports Rutgers-Camden program for science majors
10. Rutgers cell biologist pinpoints how RNA viruses copy themselves
11. Rutgers researchers discover secrets of nutritious corn breed that withstands rigors of handling
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2017)... 2017  Securus Technologies, a leading provider of ... safety, investigation, corrections and monitoring, announces the appointment ... "Too often, too many offenders return to ... are trying to tackle this ongoing problem and ... family members. While significant steps are underway, Securus continues ...
(Date:2/22/2017)... 2017 With the biometrics market to ... four technologies that innovative and agile startups must ... in the changing competitive landscape: multifactor authentication (MFA), ... "Companies can no longer afford to ... Dimitrios Pavlakis , Industry Analyst at ABI ...
(Date:2/21/2017)... February 21, 2017 Der weltweite ... wachsen. Nach einem Gespräch mit mehr als 50 Vertretern aus ... zu überwinden gilt, um diese Prognose zu realisieren. ... ... Mobilisierung der finanziellen Mittel für die Biobank, die Implementierung ...
Breaking Biology News(10 mins):
(Date:3/27/2017)... MCLEAN, Va. , March 27, 2017  Perthera,s ... Lombardi Cancer Center, Subha Madhavan , Ph.D., will ... 2017 Joint Summits Panels. On Monday, March 27, 2017, ... Precision Oncology Data More Usable for Research and Care" ... Tuesday, March 28, 2017, she will be a participant ...
(Date:3/27/2017)... MA (PRWEB) , ... March 27, 2017 , ... ... a method to engineer scalable and customizable vascular grafts in JoVE’s Video Journal, ... may lead to new and improved ways of treating coronary artery disease (CAD). ...
(Date:3/27/2017)... , March 27, 2017 Neurotrope, ... novel therapies for neurodegenerative diseases, including Alzheimer,s disease, ... its application to list the Company,s common stock ... by The NASDAQ Stock Market, a unit of ... listing, Neurotrope will ring the Opening Bell at the ...
(Date:3/24/2017)... Mar. 24, 2017 Research and Markets has ... Research - Global Strategic Business Report" report to their offering. ... This report ... in US$ Million. Annual estimates and forecasts are provided for the ... primary and secondary research. The report profiles 25 ...
Breaking Biology Technology: